Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson’s disease: behavioral, histological and biochemical studies

References

• Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology 1996;47:161S–170S.10.1212/WNL.47.6_Suppl_3.161S
   PubMed Web of Science ®Google Scholar
• Dauer W, Przedborski S. Parkinson’s disease. Neuron 2003;39(6):889–909. Review.10.1016/S0896-6273(03)00568-3
   PubMed Web of Science ®Google Scholar
• Moon HE, Paek SH. Mitochondrial dysfunction in Parkinson’s disease. Exp Neurobiol. 2015;24:103–116.10.5607/en.2015.24.2.103
   PubMed Web of Science ®Google Scholar
• Tsang AHK, Chung KKK. Oxidative and nitrosative stress in Parkinson’s disease. Biochim Biophys Acta. 2009;1792:643–650.10.1016/j.bbadis.2008.12.006
   PubMed Web of Science ®Google Scholar
• Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci. 1996;16:1066–1071.
   PubMed Web of Science ®Google Scholar
• Szabó C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov. 2007;6:917–935.10.1038/nrd2425
   PubMed Web of Science ®Google Scholar
• Bannenberg GL, Vieira HL. Therapeutic applications of the gaseous mediators carbon monoxide and hydrogen sulfide. Expert Opin Ther Pat. 2009;19(5):663–682.10.1517/13543770902858824
   PubMed Web of Science ®Google Scholar
• Kapoor A, Thiemermann C. Hydrogen sulfide, neurogenic inflammation, and cardioprotection: a tale of rotten eggs and vanilloid receptors. Crit Care Med. 2010;38:728–730.10.1097/CCM.0b013e3181cab0ee
   PubMed Web of Science ®Google Scholar
• Lee SW, Hu YS, Hu LF, et al. Hydrogen sulphide regulates calcium homeostasis in microglial cells. Glia 2006;54:116–124.10.1002/(ISSN)1098-1136
   PubMed Web of Science ®Google Scholar
• Kimura H. Hydrogen sulfide induces cyclic AMP and modulates the NMDA receptor. Biochem Biophys Res Commun. 2000;267:129–133.10.1006/bbrc.1999.1915
   PubMed Web of Science ®Google Scholar
• Nagai YM, Tsugane J, Oka H. Hydrogen sulfide induces calcium waves in astrocytes. FASEB J. 2004;2004(18):557–559.
   Google Scholar
• Kimura Y, Goto Y, Kimura H. Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. Antioxid Redox Signal. 2010;12:1–13.10.1089/ars.2008.2282
   PubMed Web of Science ®Google Scholar
• Kimura Y, Kimura H. Hydrogen sulfide protects neurons from oxidative stress. FASEB J. 2004;18:1165–1167.
   PubMed Web of Science ®Google Scholar
• Zhou CF, Tang XQ. Hydrogen sulfide and nervous system regulation. Chin Med J. 2011;124:3576–3582. Review.
   PubMed Web of Science ®Google Scholar
• Giuliani D, Ottani A, Zaffe D, et al. Hydrogen sulfide slows down progression of experimental Alzheimer’s disease by targeting multiple pathophysiological mechanisms. Neurobiol Learn Mem. 2013;104:82–91.10.1016/j.nlm.2013.05.006
   PubMed Web of Science ®Google Scholar
• Yin WL, He JQ, Hu B, et al. Hydrogen sulfide inhibits MPP+-induced apoptosis in PC12 cells. Life Sci. 2009;85:269–275.10.1016/j.lfs.2009.05.023
   PubMed Web of Science ®Google Scholar
• Hu LF, Lu M, Wu ZY, et al. Hydrogen sulfide inhibits rotenone-induced apoptosis via preservation of mitochondrial function. Mol Pharmacol. 2009;75:27–34.10.1124/mol.108.047985
   PubMed Web of Science ®Google Scholar
• Tiong CX, Lu M, Bian JS. Protective effect of hydrogen sulphide against 6-OHDA-induced cell injury in SH-SY5Y cells involves PKC/PI3K/Akt pathway. Br J Pharmacol. 2010;161:467–480.10.1111/j.1476-5381.2010.00887.x
   PubMed Web of Science ®Google Scholar
• Hu LF, Lu M, Tiong CX, et al. Neuroprotective effects of hydrogen sulfide on Parkinson’s disease rat models. Aging Cell 2010;9:135–146.10.1111/ace.2010.9.issue-2
   PubMed Web of Science ®Google Scholar
• Xie L, Hu LF, Teo XQ, et al. Therapeutic effect of hydrogen sulfide-releasing L-Dopa derivative ACS84 on 6-OHDA-induced Parkinson’s disease rat model. PLoS ONE 2013;8:e60200.10.1371/journal.pone.0060200
   PubMed Web of Science ®Google Scholar
• Shimohama S, Sawada H, Kitamura Y, et al. Disease model: Parkinson’s disease. Trends Mol Med. 2003;9:360–365.10.1016/S1471-4914(03)00117-5
   PubMed Web of Science ®Google Scholar
• Yuan H, Sarre S, Ebinger G, et al. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson’s disease. J Neurosci Methods. 2005;144:35–45.10.1016/j.jneumeth.2004.10.004
   PubMed Web of Science ®Google Scholar
• von Bohlen und Halbach O. Animal models of Parkinson’s disease. Neurodegenerative Dis. 2005;2:313–320.
   PubMed Web of Science ®Google Scholar
• Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 6th ed. San Diego, CA: Academic Press; 2007.
   Google Scholar
• Haghdoost-Yazdi H, Hosseini SS, Faraji A, et al. Long term exposure to norharman exacerbates 6-hydroxydopamine-induced parkinsonism: possible involvement of L-type Ca2+ channels. Behav Brain Res. 2010;215(1):136–140.10.1016/j.bbr.2010.07.011
   PubMed Web of Science ®Google Scholar
• Haghdoost-Yazdi H, Faraji A, Fraidouni N, et al. Significant effects of 4-aminopyridine and tetraethylammonium in the treatment of 6-hydroxydopamine-induced Parkinson’s disease. Behav Brain Res. 2011;223(1):70–74.10.1016/j.bbr.2011.04.021
   PubMed Web of Science ®Google Scholar
• Esmaeili MH, Movahedi M, Faraji A, et al. Intracerebral injection of low amounts of norharman induces moderate Parkinsonism-like behavioral symptoms in rat. Neurotoxicol Teratol. 2012;34(5):489–494.10.1016/j.ntt.2012.07.001
   PubMed Web of Science ®Google Scholar
• Abrous DN, Rodriguez JJ, Montaron MF. Behavioural recovery after unilateral lesion of the dopaminergic mesotelencephalic pathway: effect of repeated testing. Neuroscience 1998;84(1):213–221.10.1016/S0306-4522(97)00498-3
   PubMed Web of Science ®Google Scholar
• Iancu R, Mohapel P, Brundin P, et al. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson’s disease in mice. Behav Brain Res. 2005;162(1):1–10.10.1016/j.bbr.2005.02.023
   PubMed Web of Science ®Google Scholar
• Haghdoost-Yazdi H, Fraidouni N, Faraji A, et al. High intake of folic acid or complex of B vitamins provides anti-Parkinsonism effect: no role for serum level of homocysteine. Behav Brain Res. 2012;233(2):375–381.10.1016/j.bbr.2012.05.011
   PubMed Web of Science ®Google Scholar
• Bové J, Perier C. Neurotoxin-based models of Parkinson’s disease. Neuroscience 2012;211:51–76.
   PubMed Web of Science ®Google Scholar
• Kida K, Yamada M, Tokuda K, et al. Inhaled hydrogen sulfide prevents neurodegeneration and movement disorder in a mouse model of Parkinson’s disease. Antioxid Redox Signal. 2011;15:343–352.10.1089/ars.2010.3671
   PubMed Web of Science ®Google Scholar
• Lu M, Zhao FF, Tang JJ, et al. The neuroprotection of hydrogen sulfide against MPTP-induced dopaminergic neuron degeneration involves uncoupling protein 2 rather than ATP-sensitive potassium channels. Antioxid Redox Signal. 2012;17:849–859.10.1089/ars.2011.4507
   PubMed Web of Science ®Google Scholar
• Cakmak YO. Rotorua, hydrogen sulphide and Parkinson’s disease-A possible beneficial link? N Z Med J. 2017;130(1455):123–125.
   PubMed Web of Science ®Google Scholar